Anti-EGFR therapy (Nimotuzumab) plus CCRT in the treatment of LA-NPC (15, 16) and anti-PD-1/PD-L1 immunotherapy combined with chemotherapy (17, 18) in the treatment of refractory for recurrent or metastatic nasopharyngeal carcinoma (RM-NPC) have made significant progress. This evidence concerns the gene EGFR and nasopharyngeal carcinoma.